13 Oct 2022 17:55
CORRECT: Coral Products buys Ecodeck; Evgen Pharma recruits
(Correcting Harmony Energy Income Trust's use of funds.)
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
EVG.L Share News (EVG)
EVG Share
Price
EVG Share
News
EVG Share
Chat
EVG Share
Trades
EVG
Live RNS
EVG Share
Charts
EVG Broker
Ratings
EVG Directors
Deals
EVG Financial
Diary
EVG
Fundamentals
EVG Short
Positions
EVG
Media
EVG.L Information
- There is currently no data for EVG
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Richard Moulson to join Evgen Pharma as CFO
Tue, 17th Jan 2017 12:35
(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday.The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 February 2017, on which date the current CFO John Bradshaw will leave the company to focus on his work with a new healthcare investment vehicle.Moulson will then join the company's board and become CFO on 1 March.He graduated in zoology at Exeter University before qualifying as an accountant at Coopers & Lybrand.Moulson worked in corporate finance at Deutsche Morgan Grenfell for 10 years before working in financial and company secretarial roles at a number of UK biotechnology and technology companies.Since 2012, he has had a portfolio of interests, including recently as CFO of Cogent Breeding and previously as interim CFO at both ReNeuron Group and Enigma Diagnostics.Evgen also announced that David Howat, who holds the non-board position of chief development officer, will leave the company at the end of March.Howat led the preclinical and early-stage clinical development of the company's lead product - SFX-01 - through to the Phase II trials.The Phase II trials will continue to be managed by senior clinical study manager Dave Chadwick, who will assumes the non-board position of head of clinical operations on 1 March."On behalf of the board, I would like to express our sincere thanks to John Bradshaw for his valuable contribution to the development of Evgen Pharma, including his important role in the Company's IPO," said CEO Stephen Franklin."I would like to welcome Richard Moulson to Evgen Pharma," he continued."Richard is an experienced CFO with a track record in life sciences and we all look forward to his input to the company and to the board".Dr Franklin also thanked Howat for being a "tremendous asset" during Evgen's formative years and helping to take its lead product through to the current patient trials."David leaves us to join an earlier-stage company and the board extends its thanks and wishes him every success in his new role."
More News
12 Oct 2022 21:46
TRADING UPDATES: Coral Products buys Ecodeck; Evgen Pharma recruits
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more12 Oct 2022 12:23
Evgen starts recruiting volunteers for trial of lead asset
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced the start of recruitment for the pharmacokinetic and pharmacodynamic trial in healthy volunteers, and the decision to commence an investigator-sponsored clinical study for the glioblastoma programme on Wednesday.
Read more10 Oct 2022 12:10
LONDON MARKET MIDDAY: FTSE 100 trims opening loss amid Fed hike worry
(Alliance News) - European equities traded off session lows heading into Monday afternoon, finding some poise after a poor open, as markets deal with the fallout from last week's US jobs report.
Read more10 Oct 2022 11:00
AIM WINNERS & LOSERS: Europa Oil, i3 Energy slide as well disappoints
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.
Read more10 Oct 2022 09:58
Evgen Pharma shares jump 65% as licences SFX-01 composition for autism
(Alliance News) - Evgen Pharma PLC on Monday said it has signed a licencing deal for up to USD160.5 million with Stalicla SA for the global rights to its lead asset SFX-01 in neurodevelopmental disorders and schizophrenia.
Read more14 Jul 2022 16:39
UK shareholder meetings calendar - next 7 days
| Friday 15 July | |
| Aveva Group PLC | AGM |
| DCC PLC | AGM |
| DP Poland PLC | AGM |
| Griffin Mining Ltd | AGM |
| MC Mining PLC | GM re subscription |
| Monday 18 July | |
| Audioboom Group PLC | AGM |
| JPMorgan European Discovery Trust PLC | AGM |
| Tuesday 19 July | |
| Biotech Growth Trust PLC | AGM |
| Clean Power Hydrogen PLC | AGM |
| e-Therapeutics PLC | AGM |
| Norcros PLC | AGM |
| Ten Lifestyle Group PLC | GE re commitment to sustainability, B Corp certification |
| Wednesday 20 July | |
| ADM Energy PLC  | AGM |
| Alkemy Capital Investments PLC | AGM |
| DeepVerge PLC | AGM |
| easyJet PLC | GM re purchase of 56 Airbus A320neo family aircraft & conversion of 18 A320neo family aircraft |
| Fidelity China Special Situations PLC | AGM |
| HarbourVest Global Private Equity Ltd | AGM |
| HICL Infrastructure PLC | AGM |
| Novacyt SA | AGM r |
| Plaza Centers NV | AGM |
| Premier Foods PLC | AGM |
| Royal Mail PLC | AGM |
| Triad Group PLC | AGM |
| Wynnstay Properties PLC | AGM & GM re share buyback |
| Thursday 21 July | |
| Big Yellow Group PLC | AGM |
| Evgen Pharma PLC | AGM |
| Experian PLC | AGM |
| Halma PLC | AGM |
| Intermediate Capital Group PLC | AGM |
| Johnson Matthey PLC | AGM |
| Octopus AIM VCT PLC | AGM |
| Pennon Group PLC | AGM |
| Pires Investments PLC | GM re offer from Tern PLC |
| QinetiQ Group PLC | AGM |
| SSE PLC | AGM |
| Tern PLC | GM re offer for Pires Investments PLC |
| Vp PLC | AGM |
| Workspace Group PLC | AGM |
| Zephyr Energy PLC | AGM |
| Copyright 2022 Alliance News Limited. All Rights Reserved. | |
13 Jun 2022 19:22
IN BRIEF: Evgen to work with University of Michigan on asset SFX-01
Evgen Pharma PLC- Cheshire, England-based drug development company - Announces collaboration with University of Michigan, to investigate the potential anti-tumour effects of the company's lead asset SFX-01 in colorectal cancer.
Read more8 Jun 2022 14:26
Evgen Pharma starts trial to test breast cancer tablet; loss narrows
(Alliance News) - Evgen Pharma PLC on Wednesday said it would begin a trial to test a new medicinal product later this year and said its results for the most recent financial year are in line with expectations.
Read more25 May 2022 22:02
TRADING UPDATES: Tekcapital fundraise; Kromek wins US government order
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Read more18 Jan 2022 11:48
Evgen agrees fresh licensing deal with Spanish institutions
(Sharecast News) - Clinical-stage drug development company Evgen Pharma announced a memorandum of understanding with the University of Seville, Consejo Superior de Investigaciones Científicas (CSIC) and Fundación Pública Andaluza Progreso y Salud on behalf of the Institute of Biomedicine of Seville on Tuesday, for second-generation sulforaphane analogues.
Read more18 Jan 2022 11:32
Evgen signs agreement for Spanish institutions' sulfoaphane analogues
Evgen signs agreement for Spanish institutions' sulfoaphane analogues
Read more7 Dec 2021 21:49
EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
EARNINGS UPDATES: Carr's beats expectations; Premier assets hit record
Read more30 Nov 2021 16:26
UK earnings, trading statements calendar - next 7 days
UK earnings, trading statements calendar - next 7 days
Read more10 Nov 2021 18:22
TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
TRADING UPDATES: Permanent TSB sells loan portfolio; Dekel output up
Read more